Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sunitinib for imatinib-resistant GIST.

× No keyword cloud information.

14 in total

1. Emergence of secondary resistance to imatinib in recurrent gastric GIST.

Authors: Naga Venkatesh Gupta Jayanthi
Journal: J Gastrointest Surg Date: 2010-08-17 Impact factor: 3.452

Review 2. Molecular response prediction in gastrointestinal stromal tumors.

Authors: Philippe A Cassier; Jean-Yves Blay
Journal: Target Oncol Date: 2010-04-02 Impact factor: 4.493

3. Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.

Authors: Pamela Ann Harvey; Leslie Anne Leinwand
Journal: Mol Cell Endocrinol Date: 2014-10-30 Impact factor: 4.102

Review 4. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors: Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal: J Hematol Oncol Date: 2022-10-08 Impact factor: 23.168

5. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

Authors: Andrew J Wagner; Rashmi Chugh; Lee S Rosen; Jeffrey A Morgan; Suzanne George; Michael Gordon; Joi Dunbar; Emmanuel Normant; David Grayzel; George D Demetri
Journal: Clin Cancer Res Date: 2013-09-17 Impact factor: 12.531

Sunitinib for imatinib-resistant GIST.

1. Emergence of secondary resistance to imatinib in recurrent gastric GIST.

Review 2. Molecular response prediction in gastrointestinal stromal tumors.

3. Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.

Review 4. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

5. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

6. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

7. Surgery for gastrointestinal stromal tumors of the stomach.

Review 8. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Review 9. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Review 10. Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances.